Literature DB >> 22246850

The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.

Wanhua Xu1, Rong Li, Suhua Zhang, Lilin Gong, Zhihong Wang, Wei Ren, Chenxi Xia, Qifu Li.   

Abstract

Inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is considered as a major predictor of cardiovascular events. Apolipoprotein B (ApoB) directly reflects the number of plasma atherogenic lipoproteins, and may play a major role in vascular inflammation. We aimed to assess whether an association between ApoB and hsCRP exists and, furthermore, to examine whether ApoB is more predictive of the inflammatory status than other cardiovascular risk factors. This was a cross-sectional study, with 511 apparently healthy adult subjects enrolled. Waist circumference (WC), body mass index (BMI), and blood pressure (BP) were measured. Plasma glucose levels, hsCRP, lipid profile, and insulin were collected after 10-14 h fasting. From the lowest to the highest quartile of hsCRP, the values for BMI, WC, BP, HOMA-IR, insulin, glucose level, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), ApoB and the ApoB/apolipoprotein A1 (ApoA1) ratio were increased as the hsCRP level increased (P < 0.01), and high-density lipoprotein cholesterol (HDL-C) and ApoA1 levels declined as hsCRP level increased (P < 0.0001). Pearson's correlation analysis demonstrated that hsCRP correlated with all variables (P < 0.01), except for total cholesterol (TC) (P = 0.154) and LDL-C (P = 0.087). According to forward stepwise regression analysis with hsCRP as the dependent variable, WC was the only variable entered the regression model. ApoB level correlated with hsCRP level but was not the major determinant of hsCRP. WC was stronger than other cardiovascular risk factors in the associations with hsCRP. Abdominal obesity rather than atherogenic dyslipidemia was the primary cause of chronic inflammatory status.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246850     DOI: 10.1007/s12020-012-9599-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

1.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

Review 2.  Apelin, diabetes, and obesity.

Authors:  Isabelle Castan-Laurell; Cédric Dray; Camille Attané; Thibaut Duparc; Claude Knauf; Philippe Valet
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

Review 3.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

Authors:  W E Boden
Journal:  Am J Cardiol       Date:  2000-12-21       Impact factor: 2.778

4.  Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes.

Authors:  N Hyka; J M Dayer; C Modoux; T Kohno; C K Edwards; P Roux-Lombard; D Burger
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

5.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women.

Authors:  A E Hak; C D Stehouwer; M L Bots; K H Polderman; C G Schalkwijk; I C Westendorp; A Hofman; J C Witteman
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

Review 6.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

Review 7.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

8.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

9.  Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Authors:  Laurence Perségol; Bruno Vergès; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2007-02-28       Impact factor: 5.922

10.  Glycation impairs high-density lipoprotein function.

Authors:  C C Hedrick; S R Thorpe; M X Fu; C M Harper; J Yoo; S M Kim; H Wong; A L Peters
Journal:  Diabetologia       Date:  2000-03       Impact factor: 10.122

View more
  7 in total

1.  Growth hormone deficiency and cardiovascular risk: do we need additional markers?

Authors:  M Gola; A Giustina
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Vitamin D status affects the relationship between lipid profile and high-sensitivity C-reactive protein.

Authors:  Dan Jin; Dao-Min Zhu; Hong-Lin Hu; Meng-Nan Yao; Wan-Jun Yin; Rui-Xue Tao; Peng Zhu
Journal:  Nutr Metab (Lond)       Date:  2020-07-14       Impact factor: 4.169

3.  Case-Control Study to Investigate the Association Between Serum Apolipoprotein B/A1 Ratio and Atrial Fibrillation by Sex in 920 Patients from China.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng; Mengqi Yang
Journal:  Med Sci Monit       Date:  2022-05-14

4.  Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer.

Authors:  Päivi Sirniö; Juha P Väyrynen; Kai Klintrup; Jyrki Mäkelä; Markus J Mäkinen; Tuomo J Karttunen; Anne Tuomisto
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

5.  The Monitoring of Protein Markers of Inflammation and Serum Lipid Concentration in Obese Subjects with Metabolic Syndrome.

Authors:  Dragana Puhalo Sladoje; Bojana Kisić; Dijana Mirić
Journal:  J Med Biochem       Date:  2017-10-28       Impact factor: 3.402

6.  Evaluation of cardiovascular risk factors in women referring to health centers in Tabriz, Iran, 2017.

Authors:  Roghayeh Molani Gol; Maryam Rafraf; Mohammad Asghari Jafarabadi
Journal:  Health Promot Perspect       Date:  2018-10-27

7.  Association between ApoA1 Gene, Plasma Lipid Profile, hsCRP Level, and Risk of Arterial Stiffness in Thai Elderly.

Authors:  Pruttaya Supajaree; Suwannee Chanprasertyothin; Prapimporn Chattranukulchai Shantavasinkul; Piyamitr Sritara; Jintana Sirivarasai
Journal:  Adv Prev Med       Date:  2022-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.